|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table II: Baseline clinical characteristics of primary dataset and entire dataset | | | | | | | | |
| Characteristics | primary dataset | entire dataset | P-Value |  | Characteristics | primary dataset | entire dataset | P-Value |
| n=182 | n=363 |  |  | n=182 | n=363 |  |
| **Age (%)** |  |  | 0.5 |  | **M stage (%)** |  |  | 0.54 |
| <65 | 102 (56%) | 227 (63%) |  |  | M1-X | 56 (31%) | 101 (28%) |  |
| ≥65 | 80 (44%) | 136 (37%) |  |  | M0 | 126 (69%) | 262 (72%) |  |
| **Gender (%)** |  |  | 0.44 |  | **N stage (%)** |  |  | 0.69 |
| male | 116 (64%) | 245 (67%) |  |  | N1-X | 62 (34%) | 116 (32%) |  |
| female | 66 (36%) | 118 (33%) |  |  | N0 | 120 (66%) | 247 (68%) |  |
| **Family history of cancer (%)** | | | 1 |  | **T stage (%)** |  |  | 0.57 |
| YES | 66 (36%) | 133 (37%) |  |  | T1-2 | 142 (78%) | 273 (75%) |  |
| NO | 116 (64%) | 230 (63%) |  |  | T3-4 | 40 (22%) | 89 (25%) |  |
| **Residual (%)** |  |  |  |  | **Hepatitis (%)** |  |  | 0.81 |
| R0 | 162 (89%) | 326 (90%) | 0.81 |  | YES | 77 (42%) | 159 (44%) |  |
| R1-X | 20 (11%) | 37 (10%) |  |  | NO | 105 (58%) | 204 (56%) |  |
| **Histologic grade (%)** | | |  |  | **Alcohol (%)** |  |  | 0.99 |
| G1–G2 | 117 (64%) | 234 (64%) | 1 |  | YES | 62 (34%) | 122 (34%) |  |
| G3–G4 | 65 (36%) | 129 (36%) |  |  | NO | 120 (66%) | 241 (66%) |  |
| **TNM stage (%)** |  |  | 0.41 |  | **Smoking (%)** |  |  | 0.71 |
| stage i-ii | 142 (78%) | 270 (74%) |  |  | YES | 9 (5%) | 14 (4%) |  |
| stage iii-iv | 40 (22%) | 93 (26%) |  |  | NO | 173 (95%) | 349 (96%) |  |
| **Vascular invasion (%)** | | | 0.45 |  | **BMI (%)** |  |  | 0.76 |
| YES | 60 (33%) | 133 (37%) |  |  | <24 | 90 (49%) | 186 (51%) |  |
| None | 122 (67%) | 230 (63%) |  |  | ≥24 | 92 (51%) | 177 (49%) |  |